Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.

International journal of cancer - 1 Dec 2008

Jiang Shi-Xu, Yamashita Kazuya, Yamamoto Michiko, Piao Chun-Ji, Umezawa Atsuko, Saegusa Makoto, Yoshida Tsutomu, Katagiri Masato, Masuda Noriyuki, Hayakawa Kazushige, Okayasu Isao

Abstract excerpt

Gefitinib is dramatically effective for nonsmall cell lung cancers (NSCLCs) with activating mutations of the epidermal growth factor receptor (EGFR) gene, but these tumors eventually develop drug resistance, attributable to a secondary T790M mutation or acquired MET amplification in some relapsed tumors. We analyzed EGFR mutations in matched pre- and post-therapeutic tumors of 6 gefitinib-responding lung cancers....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Genetic Heterogeneity

Share to Lung Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 18785203
DOI: 10.1002/ijc.23868

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.PMID 18785203Read ↗

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingSemantic proximity Read ↗

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.Semantic proximity Read ↗

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.Semantic proximity Read ↗

Defining clinically relevant molecular subsets of lung cancer.Semantic proximity Read ↗

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerSemantic proximity Read ↗

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapySemantic proximity Read ↗

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Semantic proximity Read ↗

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Semantic proximity Read ↗

Understanding EGFR heterogeneity in lung cancer.Semantic proximity Read ↗

Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.Semantic proximity Read ↗

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.